Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring

Chronic lymphocytic leukemia (CLL) is a slow-developing, incurable leukemia. The availability of multiple diagnostic tools and platforms enables the identification of the disease and disease time course as well as better-informed treatment decisions. With the advent of advanced multiparameter flow cytometric (MFC) assays, CLL-specific molecular biomarkers may provide predictive and prognostic information, permitting population stratification into subsets defined by disease progression, response to therapy, etc.

In this session, Joseph Annunziata of Kindred Healthcare will discuss diagnostic and measurable residual disease (MRD) monitoring approaches to CLL and the benefits of predictive and prognostic assessments using multimodality peripheral blood analyses. Moreover, this talk will include an emphasis on the role of MRD in CLL drug development.

During this webinar, Annunziata will:

1. Compare various diagnostic approaches for CLL.
2. Highlight the predictive and prognostic benefits of molecular testing for CLL.
3. Assess MRD methods for long-term monitoring in CLL patients.
4. Explore the advanced role of MFC-based CLL MRD in drug research and development.

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring from Invivoscribe on Vimeo.